Arnold S. Lippa, Ph.D.
Dr. Lippa has been Executive Chairman of the Board of RespireRx Pharmaceuticals Inc. since March 2013, and has been Chief Scientific Officer since his appointment in August, 2015. From March 2013 until August 2015, he served as Chief Executive Officer and President. He is Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006.
Dr. Lippa is a Managing Member and founder of T Morgen Capital LLC, which is an investment and management company specializing in the creation and management of biomedical companies. Since 2005, T Morgen Capital has been a significant equity owner and a managing member of Aurora Capital LLC, a life science focused FINRA member firm, where Dr. Lippa represents T Morgen Capital as a Manager.
In 2004, Dr. Lippa co-founded and currently is representing T Morgen Capital, a Managing Member, as a Manager of Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life science fund management company and fund, respectively, both of which are affiliates of Aurora Capital.
Dr. Lippa was a founder of DOV Pharmaceutical, Inc. and served as Chairman of the Board and Chief Executive Officer from its inception in April 1995 until 2005. Prior to founding DOV, from 1987 until 1994, Dr. Lippa co-founded and co-managed a number of life sciences companies, including Praxis Pharmaceuticals, Inc., which Dr. Lippa co-founded and took public in 1985. He served as President and Chief Operating Officer from 1984 until 1987. Prior to 1985, he served as Director of Molecular Neurobiology and held other positions at the Medical Research Division of the American Cyanamid Corporation.
Dr. Lippa has consulted for various pharmaceutical and biotechnology companies and was a graduate faculty professor at the New York University School of Medicine and the City University of New York. Dr. Lippa has held numerous scientific and editorial positions, has testified on the development of anti-AIDS drugs before a Congressional committee and has served as a consultant and special reviewer for the National Institutes of Health and the National Science Foundation.
Mr. Purcell has been the Senior Vice-President of Research and Development for RespireRx Pharmaceuticals Inc. since 2014, leading the development of the company’s portfolio of pipeline products for respiratory indications. He is a biopharmaceutical development specialist, with extensive experience in providing consulting services to financial, venture capital, and start-up companies to concentrate on new business strategy and clinical development of novel compounds.
Mr. Purcell is also the President and CEO of intelliSantè, Inc., a private software development firm focused on patient-centric health information management systems. Previously, he was president of ClinPro, Inc., a clinical research organization (CRO), where he led this full-service, technology driven CRO specializing in Phase I, II, and III clinical trial management. His work included the design and implementation of a number of early stage clinical development programs.
Prior to joining ClinPro, he worked for SCP Communications, a medical communications company, where he served as Corporate Vice President and General Manager of the Clinical Programs Division. He previously headed the Life Sciences Consulting Group for Kline and Company.
Mr. Purcell started his career as a molecular biologist, where he developed and patented a second generation TPA with increased half-life. He has also conducted primary research and published manuscripts on the topics of AIDS and immunomodulators. He graduated from Princeton University with a degree in Biochemical Sciences, and attended Rutgers Graduate School of Management focusing on marketing and finance.
Mr. Margolis is a member of the Board of Directors, Senior Vice President, Chief Financial Officer, Treasurer and Secretary of RespireRx Pharmaceuticals Inc. and has been an executive officer and member of the Board of Directors since March 2013. He is also Chief Financial Officer and a member of the Board Directors of Xintria Pharmaceutical Corp, which he co-founded in 2006.
Mr. Margolis has served as President of Aurora Capital LLC, a boutique investment bank and securities firm specializing in the life science sector, since he founded its predecessor company, Aurora Capital Corp. in 1994. Aurora Capital Corp. was registered with the SEC and became a member of the FINRA (formerly NASD) in May 1995. Aurora Capital LLC succeeded to the business of Aurora Capital Corp. on September 16, 1998.
In 2004, Mr. Margolis co-founded and currently is a manager and indirectly a member of Atypical BioCapital Management LLC (Atypical Bio) and Atypical BioVentures Fund LLC, a life science fund management company and fund, respectively, that are affiliates of Aurora Capital. Prior to founding Aurora, Mr. Margolis was at D. Blech & Company Incorporated from 1992 until 1994, an investment banking firm specializing in biotechnology companies.
Before becoming involved in financing and advising life science companies, Mr. Margolis worked for approximately a decade for the Fundamental Brokers Group, an international affiliated group of fixed income securities brokers. His last position with the firm was chief financial officer.
Mr. Margolis currently holds the following securities industry registrations: (i) general securities principal (Series 24), (ii) registered representative (Series 7), (iii) state agent (Series 63), (iv) financial and operations principal (Series 27), (v) municipal securities principal (Series 54), (vi) options principal (Series 4).